Ironing out the details: a comprehensive review of iron therapy in heart failure.

Ravi Chotalia, Yasir Bakhit, Minesh Chotalia, Shirley Sze

Abstract read

In one paragraph

Article in The British journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ravi ChotaliaAcademic Clinical Fellow IMT3 Cardiology, Lincoln Heart Centre, Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust; Cardiorenal Research Group, Joseph Banks Laboratories, University of Lincoln.

Yasir BakhitCardiology Registrar ST6, Lincoln Heart Centre, Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust.

Minesh ChotaliaPhD Candidate and Anaesthetic Registrar, Birmingham Acute Care Research Group, University of Birmingham; Department of Anaesthetics and Critical Care, Queen Elizabeth Hospital Birmingham.

Shirley SzeAcademic Clinical Lecturer in Cardiology, Cardiology Department, Glenfield Hospital, Leicester; NIHR Leicester Biomedical Research Centre and Department of Cardiovascular Sciences, University of Leicester; Department of Population Health Sciences, University of Leicester.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency (ID) is common in patients with heart failure (HF) and is independently associated with poor outcomes, such as reduced functional capacity and quality of life, increased frailty and increased risk of HF hospitalisations and mortality. Intravenous iron has been shown to be an effective and well-tolerated therapy in patients with HF with reduced and mildly reduced ejection fraction and ID, improving quality of life and functional status and reducing the risk of HF hospitalisations. This review aims to summarise the evidence behind intravenous iron therapy in HF from recent key randomised-controlled trials. This review will also discuss the evidence for intravenous iron therapy in patients with HF with preserved ejection fraction. Ultimately, we also aim to review remaining uncertainties, such as sex-specific differences in outcomes, the optimal iron repletion and maintenance strategies, and the most accurate measures of ID in HF.

Indexed as

heart failurehospitalisationsintravenous iron therapyiron deficiency

Identifiers

PMID42719337

DOI10.5837/bjc.2026.042

PMCPMC13557134

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.